Advertisement
© Dr_Microbe/iStock
Blood-based methods using cell-free DNA (cfDNA) are under development as an alternative to existing screening tests. However, detection of cancer using tumor-derived cfDNA has proven challenging. Here Dr. Putcha et al. show that a machine learning approach using cfDNA achieved high sensitivity and specificity in a large, early-stage, colorectal cancer cohort.
To mark blood cancer awareness month the BMC Editors have carefully curated a collection of open access articles on this topic and there is an awareness quiz to test your blood cancer knowledge.
We are delighted to present a collection of all the cancer awareness campaigns completed in 2019. New content will be uploaded on a monthly basis.
We are now recruiting Associate Editors for our Editorial Board to join our team of academic editors in assessing manuscripts in the field of cancer research. Diversity in all forms will be a driving factor when selecting an individual to serve in this capacity. Please find more information and the application form here.
Gallbladder cancer is a rare malignancy of the biliary tract with a poor prognosis, frequently presenting at an advanced stage. While rare in the United States overall, gallbladder cancer has an elevated incidence in geographically distinct locations of the globe including Chile, North India, Korea, Japan and the state of New Mexico in the United States. Rama R. Gullapalli, Associate Editor for BMC Cancer provides this review.
Systematic reviews, with or without meta-analysis, play an important role today in synthesizing cancer research and are frequently used to guide decision-making. With a focus on cancer, first author, Prof Kelley, provides a practical, stepwise approach for systematically reviewing the literature and publishing the results.
© haydenbird/iStock
Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. David Palma, Robert Olson and colleagues recently found that SABR was associated with benefits in progression-free survival and overall survival in the Phase II Trial. The goal of this international, Phase III Trial is to assess the impact of SABR in patients with 4–10 metastatic cancer lesions.
Click here to view which Articles have been shared the most in the last month!
We are proud to finally present the publications from our cross-journal thematic series, Precision Oncology. This collection focuses on how precision oncology has shaped advances in the impact of non-coding RNAs in epigenetics and cancer, immunotherapy and tumor biology. Also of note are the technological developments for preclinical routines and the clinical significance of various therapies in breast, esophageal, liver, lung, ovarian cancers, among other types.
Editor
Linda Gummlich, BMC Series, London, UK
Assistant Editors
Catherine Rice, Senior Assistant Editor, BMC Series, London
William Spenceley Jones, Assistant Editor, BMC Series, London
Consulting Editors
Yanis Boumber, Fox Chase Cancer Center, USA
Ken Herrmann, Universitätsklinikum Essen, Germany
Alan Lefor, Jichi Medical University, Japan
Christophe Nicot, Kansas University Medical Center, USA
Stephen Povoski, The Ohio State University, USA
Dirk Vordermark, Martin Luther University Halle-Wittenberg, Germany
Follow Nobel Prize laureates James P. Allison's and Tasuku Honjo's footsteps and experience the genesis of a new field of cancer therapy. BMC Cancer Editorial Board Member Dr. Sheng Guo from Pittsburgh University takes us on an exciting journey of discovery...
10 December 2019
Advertisement
Citation Impact
2.933 - 2-year Impact Factor
3.424 - 5-year Impact Factor
1.015 - Source Normalized Impact per Paper (SNIP)
1.336 - SCImago Journal Rank (SJR)
Usage
3,549,437 downloads
Social Media Impact
2273 mentions
Advertisement
